Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

6 Months Ended

Jan. 31, 2020

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2020	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues	$	12,513		$	6,871		—			—		$	19,384

Operating costs and expenses:
Cost of revenues		10,243			3,332		—			—			13,575
Research and development		373			503	$	189			—			1,065
Selling, general and administrative		5,895			2,530		—		$	2,268			10,693
Legal and related expenses		38			1		—			2,021			2,060
Total operating costs and expenses		16,549			6,366		189			4,289			27,393

Operating income (loss)		(4,036	)		505		(189	)		(4,289	)		(8,009	)

Other income (expense):
Interest		(10	)		16		—			165			171
Other		16			7		—			49			72
Foreign exchange loss		—			79		—			—			79
Income (loss) before income taxes	$	(4,030	)	$	607	$	(189	)	$	(4,075	)	$	(7,687	)

Depreciation and amortization included above	$	392		$	253	$	—		$	65		$	710

Share-based compensation included in above:
Selling, general and administrative		33			22		—			247			302
Total	$	33		$	22	$	—		$	247		$	302

Capital expenditures	$	142		$	18	$	—		$	—		$	160

Three months ended January 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	12,000		$	7,327			—			—		$	19,327

Operating costs and expenses:
Cost of revenues		11,025			3,723			—			—			14,748
Research and development		—			611		$	222			—			833
Selling, general and administrative		6,200			2,981			—		$	2,316			11,497
Legal fee expense		38			1			—			1,103			1,142
Total operating costs and expenses		17,263			7,316			222			3,419			28,220

Operating income (loss)		(5,263	)		11			(222	)		(3,419	)		(8,893	)

Other income (expense):
Interest		(15	)		14			—			228			227
Other		(29	)		(4	)		—			165			132
Foreign exchange loss		—			126			—			—			126
(Loss) income before income taxes	$	(5,307	)	$	147		$	(222	)	$	(3,026	)	$	(8,408	)

Depreciation and amortization included above	$	374		$	343		$	—		$	51		$	768

Share-based compensation included in above:
Selling, general and administrative		40			26			—			225			291
Total	$	40		$	26		$	—		$	225		$	291

Capital expenditures	$	409		$	26		$	—		$	6,147		$	6,582

Six months ended January 31, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	25,293		$	14,298			—			—		$	39,591

Operating costs and expenses:
Cost of revenues		21,218			6,878			—			—			28,096
Research and development		723			1,019		$	377			—			2,119
Selling, general and administrative		12,110			5,287			—		$	4,435			21,832
Legal and related expenses		88			1			—			3,667			3,756
Total operating costs and expenses		34,139			13,185			377			8,102			55,803

Operating income (loss)		(8,846	)		1,113			(377	)		(8,102	)		(16,212	)

Other income (expense):
Interest		(22	)		34			—			396			408
Other		19			(5	)		—			185			199
Foreign exchange loss		—			270			—			—			270
Income (loss) before income taxes	$	(8,849	)	$	1,412		$	(377	)	$	(7,521	)	$	(15,335	)

Depreciation and amortization included above	$	801		$	503		$	—		$	130		$	1,434

Share-based compensation included in above:
Selling, general and administrative		67			44			—			410			521
Total	$	67		$	44		$	—		$	410		$	521

Capital expenditures	$	289		$	145		$	—		$	—		$	434

Six months ended January 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	26,297		$	14,290			—			—		$	40,587

Operating costs and expenses:
Cost of revenues		21,993			6,994			—			—			28,987
Research and development		—			1,118		$	443			—			1,561
Selling, general and administrative		12,260			5,905			—		$	4,302			22,467
Legal fee expense		74			8			—			2,361			2,443
Total operating costs and expenses		34,327			14,025			443			6,663			55,458

Operating income (loss)		(8,030	)		265			(443	)		(6,663	)		(14,871	)

Other income (expense):
Interest		(33	)		30			—			504			501
Other		11			—			—			168			179
Foreign exchange loss (gain)		—			(198	)		—			—			(198	)
(Loss) income before income taxes	$	(8,052	)	$	97		$	(443	)	$	(5,991	)	$	(14,389	)

Depreciation and amortization included above	$	777		$	685		$	—		$	72		$	1,534

Share-based compensation included in above:
Selling, general and administrative		78			50			—			398			526
Total	$	78		$	50		$	—		$	398		$	526

Capital expenditures	$	763		$	78		$	—		$	6,147		$	6,988